Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 8/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.34 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.34 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.34 |
| ▸ | AXL | P30530 | 1/20 | 0.32 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23921233 | 0.90 | ADORA3 (0.51) | ADORA3ADORA1LMNA | |
| SCHEMBL23921020 | 0.89 | ADORA3 (0.47) | ADORA3ADORA1LMNA | |
| SCHEMBL23920864 | 0.85 | ADORA3 (0.45) | ADORA3ADORA1LMNA | |
| SCHEMBL23921079 | 0.85 | ADORA3 (0.46) | ADORA3ADORA1 | |
| SCHEMBL23920978 | 0.82 | ADORA3 (0.52) | ADORA3ADORA1 | |
| SCHEMBL23920870 | 0.79 | ADORA3 (0.52) | ADORA3ADORA1 | |
| SCHEMBL23920877 | 0.78 | ADORA3 (0.49) | ADORA3ADORA1 | |
| SCHEMBL23921155 | 0.78 | ADORA3 (0.46) | ADORA3ADORA1LMNA | |
| SCHEMBL21396510 | 0.78 | ADORA3 (0.46) | ADORA3ADORA1 | |
| SCHEMBL23920929 | 0.77 | ADORA3 (0.46) | ADORA3ADORA1LMNARXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242568-A1 | POLYMER LINKED MULTIMERS OF GUANOSINE-3', 5'-CYCLIC MONOPHOSPHATES | MIRECA MEDICINES GMBH (DE) | 2023-08-03 | — | — | US | disclosed |
| US-20210317156-A1 | NEW POLYMER LINKED MULTIMERS OF GUANOSINE-3', 5'-CYCLIC MONOPHOSPHATES | MIRECA MEDICINES GMBH (DE) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242568-A1 | POLYMER LINKED MULTIMERS OF GUANOSINE-3', 5'-CYCLIC MONOPHOSPHATES | PRKG1, PRKG2, PRKAG3 | ADORA3 425/4885ADORA1 857/4885MAPK14 626/4885 |
| US-20210317156-A1 | NEW POLYMER LINKED MULTIMERS OF GUANOSINE-3', 5'-CYCLIC MONOPHOSPHATES | PRKG1, PRKG2, PDE7A | ADORA3 449/4885ADORA1 828/4885MAPK14 657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.